Free Trial

AxoGen (NASDAQ:AXGN) Receives "Overweight" Rating from Cantor Fitzgerald

AxoGen logo with Medical background
Remove Ads

Cantor Fitzgerald restated their overweight rating on shares of AxoGen (NASDAQ:AXGN - Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $24.00 price target on the medical equipment provider's stock.

Separately, Canaccord Genuity Group lifted their price objective on shares of AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $20.75.

Get Our Latest Stock Report on AxoGen

AxoGen Trading Down 0.2 %

Shares of NASDAQ:AXGN traded down $0.04 during trading on Wednesday, hitting $17.73. 636,905 shares of the company's stock were exchanged, compared to its average volume of 557,396. AxoGen has a 1-year low of $5.55 and a 1-year high of $21.00. The firm has a 50-day moving average price of $17.92 and a two-hundred day moving average price of $15.33. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. The firm has a market cap of $786.22 million, a P/E ratio of -55.41 and a beta of 1.02.

Insider Buying and Selling at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of AxoGen stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the transaction, the director now owns 97,899 shares of the company's stock, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 7.00% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AXGN. First Light Asset Management LLC raised its holdings in shares of AxoGen by 10.2% in the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock valued at $74,272,000 after purchasing an additional 416,499 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of AxoGen by 3.2% in the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider's stock valued at $14,170,000 after purchasing an additional 31,612 shares during the last quarter. Driehaus Capital Management LLC raised its holdings in shares of AxoGen by 166.0% in the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock valued at $15,729,000 after purchasing an additional 595,579 shares during the last quarter. State Street Corp raised its holdings in shares of AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider's stock valued at $12,571,000 after purchasing an additional 95,051 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of AxoGen by 13.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider's stock valued at $12,735,000 after purchasing an additional 91,984 shares during the last quarter. Institutional investors own 80.29% of the company's stock.

About AxoGen

(Get Free Report)

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.

Recommended Stories

Should You Invest $1,000 in AxoGen Right Now?

Before you consider AxoGen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.

While AxoGen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads